Patient experiences with clinical confirmatory genetic testing after using direct-to-consumer raw DNA and third-party genetic interpretation services

被引:2
|
作者
Dolphyn, Tiffany T. Nguyen [1 ,2 ]
Ormond, Kelly E. [1 ,3 ,4 ]
Weissman, Scott M. [5 ]
Kim, Helen J. [1 ]
Reuter, Chloe M. [6 ]
机构
[1] Stanford Univ, Stanford Sch Med, Dept Genet, Stanford, CA 94305 USA
[2] Stanford Univ, Stanford Sch Med, Stanford Med Clin Genom Program, Stanford, CA 94305 USA
[3] Stanford Univ, Stanford Ctr Biomed Eth, Stanford Sch Med, Stanford, CA 94305 USA
[4] Swiss Fed Inst Technol, Hlth Eth & Policy Lab, Dept Hlth Sci & Technol, CH-8092 Zurich, Switzerland
[5] Chicago Genet Consultants, Northbrook, IL 60062 USA
[6] Stanford Hlth Care, Stanford Ctr Inherited Cardiovasc Dis, Stanford, CA 94305 USA
关键词
Raw DNA; Third-party interpretation; Direct-to-consumer; Genetic testing; Precision medicine; Personal utility; FALSE-POSITIVE MAMMOGRAMS; PRIMARY-CARE PHYSICIANS; PERSONAL UTILITY; QUALITATIVE RESEARCH; CONSEQUENCES; IMPACT;
D O I
10.1093/tbm/ibac083
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Lay Summary The availability of raw DNA data and online genetic interpretation tools allow individuals to access genetic health risk information, where false-positive results exist. Little is known about the experience of individuals who discover disease-causing variant(s) through raw DNA interpretation and follow-up with medical-grade confirmatory genetic testing. This qualitative study describes the experiences of individuals who pursued medical-grade confirmatory genetic testing in the U.S. after they discovered a potential disease-causing variant in a raw DNA interpretation report. Individuals participated in semi-structured interviews, which were transcribed and inductively coded to identify themes. Of the 12 participants, 3 received medical-grade genetic testing results that confirmed disease-causing variants noted in raw DNA interpretation reports, and 9 were not confirmed. Nearly all participants described emotional distress and information-seeking behavior after discovering a disease-causing variant in raw DNA interpretation. When pursuing confirmatory genetic testing, many faced challenges with finding knowledgeable healthcare providers and obtaining insurance coverage. Despite reporting concerns over raw DNA interpretation and a desire for more safeguards, almost all participants stated interest in using the service again. Overall, participants' experiences reveal they find personal utility in raw DNA interpretation results and provide insight into opportunities for patient and provider education. This qualitative study describes the experiences of individuals who pursued clinical confirmatory genetic testing after obtaining raw DNA data from direct-to-consumer genetic testing and discovering a potential disease-causing variant from an online genetic interpretation tool. The availability of raw DNA and genetic interpretation tools allow individuals to access genetic health risk information, where analytical false-positives exist. Little is known about the experience of individuals who receive pathogenic or likely pathogenic variant(s) through raw DNA interpretation and follow-up with clinical confirmatory genetic testing. This qualitative study set out to describe the experiences of individuals who pursued clinical confirmatory genetic testing, including their perception of the process. Participants were recruited from social media and eligible if they discovered a potential pathogenic or likely pathogenic variant in a raw DNA interpretation report, completed clinical confirmatory genetic testing in the U.S., and provided documentation of those results. Individuals participated in semi-structured interviews, which were transcribed and inductively coded to identify themes. Of the 12 participants, 3 received clinical genetic testing results that confirmed pathogenic or likely pathogenic variants noted in raw DNA interpretation reports (confirmation positive), and 9 were not confirmed. Nearly all (n = 11) participants described emotional distress and information-seeking behavior as a coping mechanism after discovering a pathogenic or likely pathogenic variant in raw DNA interpretation. When pursuing confirmatory genetic testing, many (n = 9) faced challenges with finding knowledgeable healthcare providers and obtaining insurance coverage. Despite reporting concerns over raw DNA interpretation and a desire for more safeguards, almost all (n = 10) participants stated interest in using the service again. Overall, participants' experiences reveal they find personal utility in raw DNA interpretation results and provide insight into opportunities for patient and provider education.
引用
收藏
页码:104 / 114
页数:11
相关论文
共 50 条
  • [1] Direct-to-consumer raw genetic data and third-party interpretation services: more burden than bargain?
    Moscarello, Tia
    Murray, Brittney
    Reuter, Chloe M.
    Demo, Erin
    GENETICS IN MEDICINE, 2019, 21 (03) : 539 - 541
  • [2] Direct-to-consumer genetic testing with third party interpretation: beware of spurious results
    Horton, Rachel
    Crawford, Gillian
    Freeman, Lindsey
    Fenwick, Angela
    Lucassen, Anneke
    EMERGING TOPICS IN LIFE SCIENCES, 2019, 3 (06) : 669 - 674
  • [3] Consumer use and response to online third-party raw DNA interpretation services
    Wang, Catharine
    Cahill, Tiernan J.
    Parlato, Andrew
    Wertz, Blake
    Zhong, Qiankun
    Cunningham, Tricia Norkunas
    Cummings, James J.
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2018, 6 (01): : 35 - 43
  • [4] Direct-to-consumer DNA genetic testing and the GP
    Trent, Ronald
    AUSTRALIAN FAMILY PHYSICIAN, 2014, 43 (07) : 436 - 439
  • [5] Measuring the burden of direct-to-consumer genetic testing on clinical genetics services
    Tiller, J. M.
    Millward, M.
    Bogwitz, M.
    Kincaid, H.
    Taylor, S.
    Trainer, A.
    Lacaze, P.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 50 - 50
  • [6] Impact of direct-to-consumer genetic testing on Australian clinical genetics services
    Millward, Michael
    Tiller, Jane
    Bogwitz, Michael
    Kincaid, Helen
    Taylor, Shelby
    Trainer, Alison H.
    Lacaze, Paul
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2020, 63 (09)
  • [7] Direct-to-consumer genetic testing - clinical considerations
    Trent, Ronald J.
    MEDICAL JOURNAL OF AUSTRALIA, 2013, 198 (09) : 496 - 498
  • [8] Who's on third? Regulation of third-party genetic interpretation services
    Guerrini, Christi J.
    Wagner, Jennifer K.
    Nelson, Sarah C.
    Javitt, Gail H.
    McGuire, Amy L.
    GENETICS IN MEDICINE, 2020, 22 (01) : 4 - 11
  • [9] The Impact of Direct-to-Consumer Genetic Testing on Patient and Provider
    Dinulos, Mary Beth Palko
    Vallee, Stephanie E.
    CLINICS IN LABORATORY MEDICINE, 2020, 40 (01) : 61 - 67
  • [10] Sperm donor attitudes and experiences with direct-to-consumer genetic testing
    Wodoslawsky, Sascha
    Fatunbi, Joy
    Mercier, Rebecca
    Braverman, Andrea Mechanick
    F&S REPORTS, 2023, 4 (01): : 36 - 42